Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Agendia’s MammaPrint and BluePrint Genomic Assays Now Incorporated in AGO Guidelines

NextEdge Admin

13 Apr 2024

2 min 44 sec

Agendia Inc, headquartered in Irvine, California, proudly announces the inclusion of its 80-gene molecular subtyping assay, BluePrint, in the latest German Gynecological Oncology Group (AGO) guidelines. This esteemed recognition underscores BluePrint’s pivotal role in guiding neoadjuvant chemotherapy decisions for breast cancer patients.

BluePrint’s addition to the AGO guidelines complements MammaPrint, another innovative offering from Agendia. MammaPrint, the sole FDA-cleared gene expression profiling test for assessing the risk of distant metastasis, empowers clinicians to tailor treatment plans according to the tumor’s biology. With MammaPrint’s insights derived from analyzing 70 crucial genes, patients receive personalized care plans categorized into UltraLow, Low, High 1, and High 2 risk groups.

Having already earned its place in the 2017 AGO guidelines for identifying breast cancer patients who may forego chemotherapy, MammaPrint further solidified its significance in the 2023 guidelines for extended endocrine therapy. Now, both MammaPrint and BluePrint are offered together to comprehensively inform treatment decisions, a testament to their clinical value.

AGO, comprising esteemed experts in gynecological oncology and interdisciplinary fields, meticulously updates evidence-based recommendations for breast cancer diagnosis and treatment. Professor Marc Thill from Agaplesion Markus Hospital emphasizes BluePrint’s pivotal role in guiding early treatment decisions, crucial for optimal patient care.

Clinical validation through the NBRST trial underscores BluePrint’s efficacy in predicting response rates to neoadjuvant chemotherapy, thereby facilitating informed treatment decisions. Dr. William Audeh, Agendia’s CMO, lauds the inclusion of BluePrint in AGO guidelines, foreseeing its global impact on breast cancer management.

BluePrint’s unique gene expression profiling elucidates tumor biology, guiding personalized treatment pathways. By accurately classifying tumors into Luminal-type, HER2-type, or Basal-type, BluePrint ensures tailored treatment strategies, particularly crucial for aggressive Basal tumors often misclassified.